Ethical Imaginaries
By Gina Maranto, Biopolitical Times guest contributor
| 03. 30. 2011
Is each of us morally obligated to volunteer as a subject for biomedical research? Are we blameworthy if we don't sign up to participate in clinical trials? Of the several proponents of this startling notion, bioethicist John Harris put the case perhaps most forcefully in a 2005 article in the Journal of Biomedical Ethics. He contends that
the obligation to participate in research should be compelling for anyone who believes there is a moral obligation to help others, and/or a moral obligation to be just and do one's share. Little can be said to those whose morality is so impoverished that they do not accept either of these two obligations.
According to Harris, even children (providing they are competent) bear this obligation, via their parents.
In the current Hastings Center Report [subscription only], Stuart Rennie examines this point of view. He surveys three arguments advanced singly or in concert by those who claim participation is a moral imperative:
- the "rescue" argument: if one fails to participate in medical research, one fails to prevent harms and is blameworthy...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...